Limited information is available on the effects of this group of kinase inhibitors on megakaryocytes and platelets, although MEK inhibition has been associated with thrombocytopaenia.39 Hence, for combination treatments using BCL-XL antagonists and kinase inhibitors, it will be imperative to closely monitor platelet counts, as both platelet production and platelet survival may be affected. Here, BCL2L1 is linked to Thrombocytopenia.